Capricor Therapeutics Inc (NASDAQ:CAPR) Major Shareholder Purchases $14,999,997.52 in Stock

Capricor Therapeutics Inc (NASDAQ:CAPR) major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Capricor Therapeutics Stock Down 3.4 %

CAPR opened at $9.99 on Friday. The company has a market capitalization of $319.47 million, a PE ratio of -11.48 and a beta of 3.92. The firm has a 50-day simple moving average of $4.70 and a two-hundred day simple moving average of $5.28. Capricor Therapeutics Inc has a 52 week low of $2.68 and a 52 week high of $12.87.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, sell-side analysts expect that Capricor Therapeutics Inc will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of CAPR. BNP Paribas Financial Markets bought a new position in Capricor Therapeutics during the first quarter valued at $40,000. Main Street Financial Solutions LLC raised its position in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares during the last quarter. Rhumbline Advisers purchased a new position in Capricor Therapeutics in the second quarter worth about $147,000. Finally, Jump Financial LLC bought a new stake in Capricor Therapeutics during the fourth quarter worth approximately $258,000. Institutional investors own 21.68% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CAPR shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday. Maxim Group upped their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.